In vivo evidence for dysregulation of mGluR5 as a biomarker of suicidal ideation.
Margaret T DavisAnsel HillmerSophie E HolmesRobert H PietrzakNicole DellaGioiaNabeel NabulsiDavid MatuskeyGustavo AngaritaRichard E CarsonJohn H KrystalIrina EsterlisPublished in: Proceedings of the National Academy of Sciences of the United States of America (2019)
Recent evidence implicates dysregulation of metabotropic glutamatergic receptor 5 (mGluR5) in pathophysiology of PTSD and suicidality. Using positron emission tomography and [18F]FPEB, we quantified mGluR5 availability in vivo in individuals with PTSD (n = 29) and MDD (n = 29) as a function of suicidal ideation (SI) to compare with that of healthy comparison controls (HC; n = 29). Volume of distribution was computed using a venous input function in the five key frontal and limbic brain regions. We observed significantly higher mGluR5 availability in PTSD compared with HC individuals in all regions of interest (P's = 0.001-0.01) and compared with MDD individuals in three regions (P's = 0.007). mGluR5 availability was not significantly different between MDD and HC individuals (P = 0.17). Importantly, we observed an up-regulation in mGluR5 availability in the PTSD-SI group (P's = 0.001-0.007) compared with PTSD individuals without SI. Findings point to the potential role for mGluR5 as a target for intervention and, potentially, suicide risk management in PTSD.
Keyphrases
- posttraumatic stress disorder
- social support
- positron emission tomography
- major depressive disorder
- computed tomography
- randomized controlled trial
- room temperature
- depressive symptoms
- magnetic resonance imaging
- pet imaging
- pet ct
- multiple sclerosis
- white matter
- magnetic resonance
- bipolar disorder
- brain injury
- diffusion weighted imaging
- contrast enhanced